What is Sepsis Diagnostics Market?
Sepsis is a potentially life-threatening condition that occurs when the body's response to an infection damages its own tissues. When the infection-fighting processes turn on the body, they cause organs to function poorly and abnormally. The demand for sepsis diagnostic products is expected to grow mainly due to factors such as the rising prevalence of sepsis across the globe. Factors such as the increasing geriatric population, a growing number of surgical procedures, a high incidence of hospital-acquired infections, and the commercialization and availability of a wide variety of approved sepsis diagnostic devices are expected to drive market growth.
The market study is being classified by Type (Microbiology, Molecular Diagnostics, Immunoassays, Flow Cytometry, Microfluidics and Biomarkers) and major geographies with country level break-up.
bioMérieux (France), Becton Dickinson Company (United States), Danaher (United States), Abbott Laboratories (United States), Roche Diagnostics (Switzerland), T2 Biosystems (United States), Luminex (United States), Thermo Fisher Scientific (United States), Bruker (United States), EKF Diagnostics (United Kingdom) and Immunexpress (Australia) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Response Biomedical (Canada), Axis-Shield Diagnostics (United Kingdom) and CytoSorbents (United States)..
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Sepsis Diagnostics market throughout the predicted period.
Analyst at AMA have segmented the market study of Global Sepsis Diagnostics market by Type, Application and Region.
On the basis of geography, the market of Sepsis Diagnostics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- The demand for sepsis diagnostics is increasing due to the burden of sepsis-associated mortality has increased owing to the marked rise in the number of sepsis cases
- Ongoing efforts by clinicians, administrators, policymakers, and patient advocates to increase sepsis awareness, screening, and recognition are leading to more patients being labelled with sepsis
- Increasing use of hospice for end-of-life care
- Lack of a gold standard test and subjectivity in diagnosing sepsis
- Increasing awareness of sepsis among providers is a major focus of the Surviving Sepsis Campaign and of many quality improvement initiatives that have proliferated in hospitals around the world.
- The high cost of automated diagnostic devices
Market Leaders and some development strategies
In April 2020 CytoVale United States-based, a commercial physical and biological research and development firm. The firm will expand its partnership with the Biomedical Advanced Research and Development Authority(BARDA), to examine the use of Cytovale’s Rapid Sepsis Diagnostic System for diagnosing sepsis in patients with potential respiratory infections, including COVID-19, according to a press release.
In October 2020 IMMUNEXPRESS a molecular diagnostic company and a pioneer in the analysis of the immune system to rapidly detect sepsis. The company launched the test for sepsis in Europe on Biocartis’ Idylla platform. SeptiCyte® RAPID is a one-hour molecular diagnostic test running on the Biocartis Idylla platform that can swiftly differentiate infection positive (sepsis) from infection negative systemic inflammation in patients.
Key Target AudienceNew Entrants/Investors, Analysts and Strategic Business Planners, Sepsis Diagnostics Providers, Government Regulatory and Research Organizations and End-Use Industry
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase